Lundbeck in the news

Barclays raised Lundbeck's price target to 50 Danish kroner from 48 while reiterating an 'equal weight' rating.

Lundbeck partnered with AI startup Cradle to use AI for optimizing biotherapeutics and accelerating drug discovery for neurological conditions.

Torm, Norden, and Lundbeck are top performers in the Danish stock market, with Lundbeck's A and B shares showing gains.

Lundbeck is presenting preclinical data on bexicaserin's dual mode of action, which increases inhibitory and decreases excitatory neuronal activity, at the European Epilepsy Congress.

Lundbeck is moving into a "scaling phase" to expand globally, advance its pipeline, and strategically deploy capital after completing its rebuilding phase.

Lundbeck is set to present preclinical data for its epilepsy drug candidate, bexicaserin, at the European Epilepsy Congress.

Lundbeck is repurposing AprilBio's drug candidate APB-A1, originally for thyroid eye disease, to target neuroimmunological diseases.

H. Lundbeck reported strong Q2 2026 results and confirmed full-year guidance, with its stock trading below analyst targets and intrinsic value despite pipeline potential, while facing risks from R&D spending and a concentrated drug portfolio.

Eversana, in partnership with Google, has expanded its AI Agency platform for life sciences, with Lundbeck adopting it broadly across its U.S. commercial operations to accelerate its commercial model.

Novo and Lundbeck's joint venture, Quantumcell, secured a significant Alzheimer's deal after extensive evaluation of a Swedish company.

Lundbeck advanced multiple neurological drug candidates through clinical trials, gained regulatory approvals, and announced executive and financial updates.

Lundbeck is expanding its AI partnership with Eversana to enhance biopharmaceutical commercialization in the US.

Lundbeck obtained EU orphan status for asedebart, an anti-ACTH antibody for Cushing's syndrome, indicating its potential as a first-in-class treatment for rare ACTH-driven conditions.

Lundbeck's drug candidate for Cushing's syndrome has received coveted status in the EU, showing promising results for the rare hormonal disorder.

Lundbeck is expanding its partnership with Eversana to integrate AI-powered commercialization across its U.S. operations.

The European Commission granted orphan designation to Lundbeck's asedebart for Cushing's syndrome of endogenous origin, recognizing the unmet medical need for this rare disease.

Lundbeck and Eversana have announced a strategic partnership.

Lundbeck partnered with EVERSANA to integrate AI across its U.S. commercial operations, enhancing strategy, content, and execution.

Lundbeck obtained a desirable EU status for a rare disease drug candidate, offering regulatory advantages.

Lundbeck partnered with EVERSANA to advance AI-powered commercialization in its U.S. operations, leveraging EVERSANA's AI Agency platform to accelerate strategic planning, content creation, and omnichannel engagement.